Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45-70
SponsorInCor Heart Institute

About this trial

Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Postmenopausal women;

Diagnosed coronary artery disease;

Stable coronary disease;

Disqualifiers

Hypo- or hyperthyroidism,

Rheumatic disease,

Use of alcohol,

hepatic failure,

Trial design

Design model

Parallel

Treatments tested in this trial

  • Trans-resveratrol, 1000 mg daily for 90 days

    Dietary supplement

    Trans-resveratrol, 1000 mg daily for 90 days

  • Placebo

    Other intervention

    Starch, 1000 mg daily for 90 days

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: ResveratrolExperimental treatment 1 intervention
Group B: ControlPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

1. Sirtuin-1 and sirtuin-3

Serum concentrations and gene expression

Time frame
90 days
2

Estradiol

Serum concentrations

Time frame
90 days
3

Estrone

Serum concentrations

Time frame
90 days
4

SHBG

Serum concentrations

Time frame
90 days

Secondary outcomes

1

Estrogen receptor alpha

Gene expression

Time frame
90 days
2

Cardiometabolic risk factors

Lipid and glucometabolic profiles

Time frame
90 days
3

BMI

kg/m²

Time frame
90 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.